Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma (DLBCL)
DRUG: Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）
Overall Response Rate (ORR), The proportion of subjects who achieves a best overall response of CR or PR., 28days after the end of treatment
Complete Remission Rate（CRR）, The proportion of subjects who achieves a best overall response of CR., 28days after the end of treatment|Disease-control Rate（DCR）, The proportion of subjects response of CR, PR, or SD, 28days after the end of treatment|Progression-Free Survival（PFS）, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, Up to 2 years|overall survival（OS）, The overall survival time refers to the time from therapy to death due to any cause., Up to 2 years|Adverse event rate, The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)., From date of first day of treatment until 30 day after last treatment
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)